Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 19,000 shares, a decrease of 92.1% from the December 31st total of 241,700 shares. Based on an average trading volume of 325,400 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.3% of the shares of the company are short sold.
Analyst Ratings Changes
Separately, StockNews.com started coverage on Aptevo Therapeutics in a report on Monday, December 9th. They issued a “sell” rating on the stock.
Read Our Latest Stock Report on APVO
Aptevo Therapeutics Stock Performance
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Read More
- Five stocks we like better than Aptevo Therapeutics
- What is diluted earnings per share (Diluted EPS)?
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity
- EV Stocks and How to Profit from Them
- ASML: Strengths and Upside Remain Despite DeepSeek Worries
- NYSE Stocks Give Investors a Variety of Quality Options
- Royal Caribbean Soars, But Smooth Sailing Isn’t Guaranteed
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.